Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative (ER-Negative) Breast Cancer”

820 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 820 results

Testing effectiveness (Phase 2)Ended earlyNCT00417885
What this trial is testing

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer 6
Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Not applicableStudy completedNCT05673850
What this trial is testing

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

Who this might be right for
Breast Neoplasms
Peking University 518
Large-scale testing (Phase 3)Active Not RecruitingNCT06062810
What this trial is testing

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Who this might be right for
Breast Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair 600
Early research (Phase 1)Looking for participantsNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 48
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Testing effectiveness (Phase 2)Study completedNCT02598557
What this trial is testing

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Who this might be right for
Stage 0 Breast Cancer AJCC v6 and v7Stage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
National Cancer Institute (NCI) 180
Not applicableLooking for participantsNCT06681064
What this trial is testing

Breast Cancer Evolution During Neoadjuvant Systemic Therapy

Who this might be right for
Breast CancerTriple Negative Breast CancerER+ Breast Cancer+1 more
Royal Marsden NHS Foundation Trust 500
Early research (Phase 1)WithdrawnNCT01320787
What this trial is testing

18-F-Fluoroacetate as PET Imaging Agent

Who this might be right for
Brain CancerBreast CancerProstate Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Study completedNCT00629616
What this trial is testing

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 116
Testing effectiveness (Phase 2)Looking for participantsNCT04824014
What this trial is testing

4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Who this might be right for
ER+ Breast Cancer
Centre de recherche du Centre hospitalier universitaire de Sherbrooke 150
Testing effectiveness (Phase 2)Study completedNCT00003199
What this trial is testing

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerInflammatory Breast Cancer+5 more
Fred Hutchinson Cancer Center 50
Testing effectiveness (Phase 2)Ended earlyNCT02202746
What this trial is testing

Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerMBC+5 more
Clovis Oncology, Inc. 178
Large-scale testing (Phase 3)Looking for participantsNCT05774951
What this trial is testing

Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Who this might be right for
Breast Cancer, Early Breast Cancer
AstraZeneca 4,300
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Load More Results